March 4, 2024 News by Marisa Wexler, MS ACTRIMS 2024: Vidofludimus calcium lowers NfL levels in progressive MS Treatment with Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium (IMU-838) lowered the levels of a nerve damage marker in people with all subtypes of progressive multiple sclerosis (MS), including those without recent inflammatory activity. That’s according to an interim analysis of data from a Phase 2 study,…
November 27, 2023 News by Margarida Maia, PhD New US patent likely to cover all vidofludimus calcium doses in MS The Patent and Trademark Office intends to grant a U.S. patent covering all dosing regimens of vidofludimus calcium ā being developed as IMU-838 ā for the treatment of multiple sclerosis (MS). That includes the doses being used in developer Immunic Therapeuticsā ongoing clinical program, according to a…
November 6, 2023 News by Margarida Maia, PhD US patent likely for vidofludimus calcium at relapsing MS trial dose Immunic Therapeutics has been notified of the intent to grant a U.S. patent covering the use vidofludimus calcium (IMU-838) in treating relapsing forms of multiple sclerosis (MS)Ā at a daily dose of about 10 to 45 mg. That range covers the two IMU-838 doses shown to be…
October 12, 2023 News by Patricia Inacio, PhD Vidofludimus calcium reduced NfL levels in progressive MS patients Vidofludimus calcium (IMU-838), an investigational oral therapy being developed byĀ Immunic Therapeutics for all types of multiple sclerosis (MS), has demonstrated neuroprotective effects in people with progressive forms of the disease, interim clinical trial data show. The experimental therapy was associated with reductions in neurofilament light chain (NfL)…
August 22, 2023 News by Patricia Inacio, PhD Progressive MS trial of vidofludimus calciumĀ fully enrolled A global Phase 2 clinical trial investigating theĀ oral therapy vidofludimus calcium (IMU-838) in people with progressive forms of multiple sclerosis (MS) has reached full enrollment, the treatment’s developer, Immunic Therapeutics, reports. Called CALLIPER (NCT05054140), the trial is assessing whether the neuroprotective effects of vidofludimus calciumĀ seen in…
June 2, 2023 News by Marisa Wexler, MS Vidofludimus calcium tolerated well for nearly 4 years Long-term treatment with vidofludimus calcium (IMU-838) has been tolerated well overall among people with relapsing-remitting MS (RRMS), new data from an extension study show. Findings were presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, in a poster titled “Assessment of Long-Term Safety…
May 18, 2023 News by Lindsey Shapiro, PhD Experimental MS therapy vidofludimus calcium triggers Nurr1 protein Vidofludimus calcium (IMU-838), an investigational multiple sclerosis (MS) therapy with promising results in clinical trials, may exert neuroprotective effects by activating a protein called Nurr1, according to newly published preclinical data. The observed actions on Nurr1 are in addition to the therapy’s known role as an inhibitor of…
March 7, 2023 News by Lindsey Shapiro, PhD ACTRIMS 2023: RRMS treatment may ‘give patients a better choice’ New data from a Phase 2 clinical trial testing vidofludimus calcium, Immunic Therapeuticsā novel oral treatment candidateĀ for relapsing-remitting multiple sclerosis (RRMS), show promising safety and efficacy, according to the company’s chief medical officer. The therapy was found to safely reduce brain lesions and prevent disability progression in…
November 21, 2022 News by Marisa Wexler, MS 2 Years of Vidofludimus Calcium Thwarts Disability Progression: Data Most adults with relapsing-remitting multiple sclerosis (RRMS) who received Immunic Therapeutics‘ investigational therapy vidofludimus calcium have had no confirmed disability progression after two years of treatment. That’s according to new interim data from the open-label extension portion of the EMPhASIS trial, which has been running for nearly…
June 20, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: Vidofludimus Calcium, Foralumab, Exoskeleton, Dysport Vidofludimus Calcium Safely Reduced RRMS Brain Lesions Vidofludimus calcium, also called IMU-838, is an oral therapy designed to reduce the activity of B- and T-cells. These are immune cells believed to be responsible for the inflammation that results in MS damage. In this small study, active lesions ā including…
June 17, 2022 News by Marisa Wexler, MS Vidofludimus Calcium Safely Reduced RRMS Brain Lesions Treatment with the experimental immune-modulating therapy vidofludimus calcium reduced disease activity on MRI scans in adults with relapsing-remitting multiple sclerosisĀ (RRMS), data from the Phase 2 EMPhASIS clinical trial shows. Top-line results from EMPhASIS were reported by the therapy’s developer Immunic Therapeutics in 2020. Researchers at…
November 24, 2021 News by Marisa Wexler, MS 1st Patient Enrolled in ENSURE Trials of IMU-838 in RRMS Immunic TherapeuticsĀ has enrolled the first participant in its Phase 3 ENSURE clinical trial program, which is testing the company’s investigational treatment IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS). “Enrollment of the first patient in ENSURE … marks an important inflection point for Immunic as we…